These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2149283)

  • 1. Phase II trials with toremifene in advanced breast cancer: a review.
    Valavaara R
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S31-5. PubMed ID: 2149283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer].
    Konstantinova MM; Gershanovich MA
    Vopr Onkol; 1990; 36(10):1182-6. PubMed ID: 2147527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.
    Pyrhönen S; Valavaara R; Heikkinen M; Rissanen P; Blanco G; Nordman E; Holsti LR; Hajba A
    J Steroid Biochem; 1990 Jun; 36(3):227-8. PubMed ID: 2142239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication.
    Modig H; Borgström S; Nilsson I; Westman G
    J Steroid Biochem; 1990 Jun; 36(3):235-6. PubMed ID: 2142242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
    Kohler PC; Hamm JT; Wiebe VJ; DeGregorio MW; Shemano I; Tormey DC
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S19-26. PubMed ID: 2149280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
    Gundersen S
    J Steroid Biochem; 1990 Jun; 36(3):233-4. PubMed ID: 2142241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study.
    Hietanen T; Baltina D; Johansson R; Numminen S; Hakala T; Helle L; Valavaara R
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S37-40. PubMed ID: 2149284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.
    Bishop J; Murray R; Webster L; Pitt P; Stokes K; Fennessy A; Olver I; Leber G
    Cancer Chemother Pharmacol; 1992; 30(3):174-8. PubMed ID: 1385761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of toremifene in breast cancer patients. A phase II study.
    Valavaara R; Pyrhönen S; Heikkinen M; Rissanen P; Blanco G; Nordman E; Taskinen P; Holsti LR; Hajba A
    J Steroid Biochem; 1990 Jun; 36(3):229-31. PubMed ID: 2142240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of toremifene in patients with advanced cancer.
    Hamm JT; Tormey DC; Kohler PC; Haller D; Green M; Shemano I
    J Clin Oncol; 1991 Nov; 9(11):2036-41. PubMed ID: 1834808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction to toremifene.
    Kangas L
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S3-7. PubMed ID: 2149282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.
    Modig H; Borgström S; Nilsson I; Westman G
    J Steroid Biochem; 1990 Jun; 36(3):237-8. PubMed ID: 2142243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study.
    Valavaara R; Pyrhönen S; Heikkinen M; Rissanen P; Blanco G; Thölix E; Nordman E; Taskinen P; Holsti L; Hajba A
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):785-90. PubMed ID: 2968265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment.
    Jönsson PE; Malmberg M; Bergljung L; Ingvar C; Ericsson M; Ryden S; Nilsson I; Terje IJ
    Anticancer Res; 1991; 11(2):873-5. PubMed ID: 1829600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of toremifene, a new antiestrogen.
    Hamm JT
    Cancer Invest; 1990; 8(2):273-4. PubMed ID: 2144786
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication.
    Ebbs SR; Roberts J; Baum M
    J Steroid Biochem; 1990 Jun; 36(3):239. PubMed ID: 2142244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of toremifene in breast cancer patients. Preliminary communication.
    Hindy I; Juhos E; Szántó J; Számel I
    J Steroid Biochem; 1990 Jun; 36(3):225-6. PubMed ID: 2142238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III studies of toremifene in metastatic breast cancer.
    Pyrhönen SO
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S41-6. PubMed ID: 2149285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
    Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
    Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant trials of toremifene vs tamoxifen: the European experience.
    Holli K
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.